Schizophrenia studies

AVATAR_VRSocial therapy for auditory verbal hallucinations in early psychosis

This study isn't currently recruiting.

Countries

Germany

Sponsor

Ruhr University Bochum

A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Poland, Spain

Sponsor

GW Research Ltd.

How does the regular standardized assessment of antipsychotic-induced side effects in forensic psychiatric patients affect the management of these side effects?

This study ended early.

Countries

United Kingdom

Sponsor

Department of Health (UK)

Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Universität zu Köln

RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

AstraZeneca GmbH

Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Netherlands

Sponsor

erasmus mc

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

United Kingdom

Sponsor

Boehringer Ingelheim Limited

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria, Hungary

Sponsor

Cerevel Therapeutics, LLC

Are the psychoto-mimetic effects of cannabis mediated via dopamine?

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

Does oral N-acetyl-cysteine (NAC) improve schizophrenia symptoms?

This study isn't currently recruiting.

Countries

United States, Switzerland

Sponsor

Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland)

LEGS Cluster study: Liaison with Education and General Practices to Detect and Refine Referrals of People with At-Risk-Mental-States (ARMS)

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Cambridgeshire and Peterborough NHS Foundation Trust (UK)

Supervised treatment for outpatients with schizophrenia (STOPS+)

This study isn't currently recruiting.

Countries

United Kingdom, Pakistan

Sponsor

Khyber Medical University